Jump to content

Talk:Indiana Biosciences Research Institute

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Ibricommsdirector

[edit]

I understand I may have a conflict of interest as I am the director of communications and engagement at the Indiana Bioscience Research Institute. I simply endeavor to update the entry to align with our current strategy and updated website that clearly identifies current board members, etc. Ibricommsdirector (talk) 15:51, 2 August 2022 (UTC)[reply]

{{request edit}} Please change opening short description to align with this organization's current strategy as reflected on its website, www.indianabiosciences.org.
A more appropriate short description might read, "The Indiana Biosciences Research Institute (IBRI) is an American nonprofit headquartered in Indianapolis, Indiana, within the 16 Tech Innovation District. The IBRI is a leading translational research institute that advances academic and industry science through collaboration to improve patient health outcomes. Its primary focus is on better understanding the pathogenesis of type 1 and type 2 diabetes. Its goal is to translate this knowledge into novel therapies, while also looking to expand into other diseases that share common systems and pathways." Ibricommsdirector (talk) 16:05, 2 August 2022 (UTC)[reply]
{{request edit}} Please add other social media channels to the external links.
IBRI on LinkedIn - https://www.linkedin.com/company/indiana-biosciences-research-institute
IBRI on Instagram - https://www.instagram.com/inbiosciences/
IBRI on Facebook - https://www.facebook.com/INBiosciences/ Ibricommsdirector (talk) 16:12, 2 August 2022 (UTC)[reply]
{{request edit}} Please remove the IBRI Scientific Advisory Board list as the organization no longer uses this board. Ibricommsdirector (talk) 16:16, 2 August 2022 (UTC)[reply]
{{request edit}} Please update the IBRI's Board of Directors to reflect the current list that includes:
Robert Bernhard, University of Notre Dame
Wayne Burris, Roche Diagnostics Corporation
Kenneth Custer, Eli Lilly and Company
Daniel Evans, Jr., Indiana University Health
Tatiana Foroud, Indiana University School of Medicine
Jay Hess, Indiana University
David Ingram, Indiana University Health
Cris Johnston, Indiana Office of Management and Budget
John Lechleiter, Eli Lilly and Company
Patricia Martin, BioCrossroads, Inc.
Theresa Mayer, Purdue University
Hany Moselhi, Roche Diagnostics North America
Alan Palkowitz, Indiana Biosciences Research Institute
Dan Peterson, Cook Group, Inc.
Aaron Schacht, BiomEdit, LLC
Wendy Srnic, Corteva Agriscience
Bill Stephan, Indiana University Ibricommsdirector (talk) 16:21, 2 August 2022 (UTC)[reply]